Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients no younger than 18 years of age~* Recently diagnosed pulmonary hypertension (defined by RV systolic pressure of ≥ 40 mmHg as measured by echocardiography), going for invasive hemodynamic assessment for pulmonary hypertension~* Normal left ventricular function defined as a left ventricular ejection fraction (LVEF) greater than or equal to 50%~Exclusion Criteria:~* Heart failure (LVEF \< 50%, diastolic dysfunction \> stage 1, history or symptoms of left heart failure) - Group II pulmonary hypertension~* 2+ or higher MR or AI~* Inadequate echocardiographic windows~* Pregnancy~* Systolic blood pressure ≤ 90 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iloprost and nitric oxide administration (Type: EXPERIMENTAL): Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).